HO-1 impairs the efficacy of radiotherapy by redistributing cGAS and STING in tumors
Journal of Clinical Investigation · 02.12.2024 · 134 (23)
DOI: 10.1172/jci181044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 02.12.2024. Verfasst von Chuqing Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carci…. Hauptthemen laut MEDLINE: Nucleotidyltransferases, Membrane Proteins, Heme Oxygenase-1. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, Guangzhou Municipal Health Commission, Cancer Innovative Research Program of Sun Yat-sen University Cancer Center.
Abstract (Originalsprache)
Type I IFNs (IFN-Is) induced by radiotherapy (RT) are critical for its efficacy, while the mechanism by which tumor cells inhibit IFN-I production remains largely unsolved. By an unbiased CRISPR screen, we identified hemeoxygenase 1 (HO-1) as an RT-related regulator of IFN-I production. Mechanistically, the ER-anchored, full-length HO-1 disrupted stimulator of IFN genes (STING) polymerization and subsequent coat protein complex II–mediated (COPII-mediated) ER-Golgi transportation, leading to hampered activation of downstream signaling. This process was exacerbated by the upregulation of HO-1 expression under RT. Importantly, RT also induced HO-1 cleavage. Cleaved HO-1 underwent nuclear translocation, interacted with cyclic GMP-AMP synthase (cGAS), and inhibited its nuclear export upon irradiation, leading to suppressed 2′3′-cyclic GMP-AMP (cGAMP) production. Furthermore, we revealed that HO-1 inhibitors could enhance local and distant tumor control of RT in vivo. Clinically, higher HO-1 expression was associated with a poorer prognosis and earlier tumor relapse after RT in multiple types of patient tumors. Collectively, through comprehensive inhibition of the cGAS/STING pathway, HO-1 strongly inhibited RT-induced IFN-I production, and targeting HO-1 was shown to be a promising RT-sensitizing therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Cen…
- Department of Radiation Oncology.
- Department of Pathology.
- Department of Ultrasound and Electrocardiography.
- Department of Nuclear Medicine, and.
- Department of Medical Imaging, Sun Yat-sen University Cancer Center, Guangzhou, China.
Förderung
- the National Natural Science Foundation of China
- Guangzhou Municipal Health Commission
- Cancer Innovative Research Program of Sun Yat-sen University Cancer Center
- Overseas Expertise Introduction Project for Discipline Innovation
- Young Talents Program of Sun Yat-sen University Cancer Center
- Basic and Applied Research Project of Science and Technology of Guangzhou city
Zitieren
APA
Zhang, C., Deng, Z., Wu, J., Ding, C., Li, Z., Xu, Z., Chen, W., Yang, K., Wei, H., He, T., Long, L., Ma, J., Xu, C., & Liang, X. (2024). HO-1 impairs the efficacy of radiotherapy by redistributing cGAS and STING in tumors. Journal of Clinical Investigation, 134(23). https://doi.org/10.1172/jci181044
Vancouver
Zhang C, Deng Z, Wu J, Ding C, Li Z, Xu Z, et al. HO-1 impairs the efficacy of radiotherapy by redistributing cGAS and STING in tumors. Journal of Clinical Investigation. 2024;134(23). doi:10.1172/jci181044
BibTeX
@article{Zhang2024,
author = {Zhang, Chuqing and Deng, Zhenji and Wu, Jiawei and Ding, Cong and Li, Zhe and Xu, Zhimin and Chen, Weipeng and Yang, Kaibin and Wei, Hanmiao and He, Tingxiang and Long, Liufen and Ma, Jun and Xu, Cheng and Liang, Xiaoyu},
title = {HO-1 impairs the efficacy of radiotherapy by redistributing cGAS and STING in tumors},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {23},
doi = {10.1172/jci181044}
}
EUVIMED